The management of hepatitis C

Minerva Gastroenterologica e Dietologica

Volumn 55, Issue 1, 2009, Pages 23-35

  Pan, J J ^a   Firpi, R J ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatitis C; Interferon alfa; Peginterferon alfa; Protease inhibitors; Reverse transcriptase inhibitors; Ribavirin

Indexed keywords

4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; ALANINE AMINOTRANSFERASE; ALBINTERFERON ALPHA2B; ALPHA2A INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; CILUPREVIR; COLCHICINE; DIDANOSINE; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; R 7128; RIBAVIRIN; STAVUDINE; TELAPREVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANEMIA; ANOREXIA; BIRTH DEFECT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COUGHING; CYTOPENIA; DEPRESSION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HALF LIFE; FATIGUE; FEVER; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; GOUT; HAIR LOSS; HEADACHE; HEARING LOSS; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; LIVER CIRRHOSIS; LIVER FIBROSIS; MEMORY DISORDER; MITOCHONDRIAL TOXICITY; MIXED INFECTION; MONOTHERAPY; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PHARMACOGENETICS; PHARYNGITIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SKIN IRRITATION; THYROID FUNCTION; TINNITUS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS GENOME; VIRUS LOAD; VISUAL DISORDER; WEIGHT REDUCTION;

GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; PROTEASE INHIBITORS;

EID: 67649407890     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
2. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997;25:1527-38.
3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 20Ol;345:4l-52.
4. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998;143:2493-503.
5. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008;372:321-32.
6. McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A et al. Asian Pacific-Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:6l5-33.
7. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:S21-9.
8. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:ll47-71.
9. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17- year cohort study of 214 patients. Hepatology 2006;43:1303-10.
10. Shiftman ML, Diago M, Tran A, Pockros P, Reindolkr R, Prati D et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006;4:645-52.
11. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
12. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:l666-72.
13. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
14. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
16. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-31.
17. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7.
18. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998;28:960-4.
19. Layden-Aimer JE, Layden TJ. Viral kinetics in hepatitis C virus: special patient populations. Semin Liver Dis 2003;23 (Suppl D-.29-33.
20. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M etal. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001;120:l438-47.
21. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2OO3;37:1351-8.
22. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL, Jr. et al. Predicting sustained virolog-ical responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33.
23. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34.
24. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kdVribavirin therapy. Hepatology 2006;43:954-60.
25. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
26. McHutchison JG, Shad JA, Gordon SC, Morgan TR, Ling MH, Garaud JJ etal. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 2001 ;8:414-20.
27. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
28. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2OO6;131:451-6O.
29. Willems B, Hadziyannis SJ, Morgan TR, Diago M, Marcellin P, Bernstein D et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotypes 2/3 without a rapid virologic response? J Hepatol 2006;46 (Suppl 1):S6.
30. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002;123:2082-99.
31. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71.
32. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004;39:1702-8.
33. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N etal. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-7.
34. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003;37:1343-50.
35. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM et al. Virologic responses to pegifna-2a/ribavirin in treatment-naive Latino vs. non-Latino Caucasians infected with HCV genotype 1: the Latino study. Gastroenterology 2008; 134 (4 Suppl D-.A-755.
36. Jacobson IM, Brown RS, Jr., McCone J, Black M, Albert C, Dragutsky MS et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007;46:982-90.
37. Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008;48:1033-43.
38. Dalgard O, Bjoro K, Helium KB, Myrvang B, Ritland S, Skaug K et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5.
39. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3- N Engl J Med 2005;352:2609-17.
40. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
41. McHutchison JG. Manns M, Patel K, Poynard T, Lindsay KL, Trepo C et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:106l-9.
42. Curry MP, Afdhal NH. Use of growth factors with antiviral therapy for chronic hepatitis C. Clin Liver Dis 2005:9:439-51.
43. Asnis GM, De La Garza R, 2nd. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006;40:322-35.
44. Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007:46:371-9.
45. Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC, Ji.et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005;100:2453-62.
46. Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL etal. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonre-sponder patients. Gastroenterology 2006;130:1098-1106.
47. Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006;55:l631-8.
48. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman 2 etal. Impact of pegylated interferon alfa-2b and ribavirin on liver flbrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
49. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC etal. Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. N EnglJ Med 2008;359:2429-41.
50. Afdhal NH, Levine R, Brown Jr. R, Freilich B, O'Brien M, Brass C. Colchicin versus peg-interferon alfa 2b long term therapy: results of the 4 year COPILOT trial. J Hepatol 2008;48 (Suppl 2):S4.
51. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
52. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N EnglJ Med 2004;351:451-9.
53. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A etal. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48.
54. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-36.
55. Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol 2008;23:1000-8.
56. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280-l.
57. Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004;38:e79-80.
58. Alvarez D, Dieterich DT. Brau N, Moorehead L. Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. | Viral Hepat 2006:13:683-9.
59. Subramanian GM, Fiscella M, Lamouse-Smith A. Zeuzem S, McHutchison JG. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007,25:1411-9.
60. Zeuzem S, Yoshida EM, Benhamou Y. Pianko S. Bain VG, Shouval D et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008;48:407-17.
61. Bain VG, Kaita KD, Marotta P. Yoshida EM, Swain MG. Bailey RJ et al. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008;6:701-6.
62. Human Genome Sciences modifies dosing in Achieve trials of albuferon [press release]. Cambridge, MA: Human Genome Sciences; January 23. 2008.
63. Huang Z, Murray MG, Secrist JA, 3rd. Recent development of therapeutics for chronic HCV infection. Antiviral Res 2006:71:351-62.
64. Sulkowski MS. Specific targeted antiviral therapy for hepatitis C. Curr Gastroenterol Rep 2007;9:5-13-
65. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-9.
66. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127:1347-55.
67. Reesink HW, Zeuzem S. Weegink CJ, Forestier N. van Vliet A, van de Wetering de Rooij J et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006:131:997-1002.
68. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B. Muh U. Welker M et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77.
69. Jacobson IM, Everson GT, Gordon SC, Kauffman R. McNair L, Muir AJ et al. Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C. Hepatology 2007;46 (Suppl 1):315A.
70. Hezode C, Ferenci P, Dusheiko GM, Pol S. Goeser T. BronowickiJ-P etal. PROVE2: phase II study of VX950 (telaprevir) in combination with peginterferon alfa 2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. Hepatology 2007:46 (Suppl 1):268A.
71. MchutchisonJG, Everson GT, Gordon SC, Jacobson I. Kauffman R, McNair L et al. PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C. J Hepatol 2008;48 (Suppl 2):S4.
72. Dusheiko GM, Hezode C, Pol S, Goeser T, Bronowicki J-P, Bourliere M et al. Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginter-feron-alfa-2a with or without ribavirin: further interim analysis results of the PROVE2 study. J Hepatol 2008:48 (Suppl 2):S26.
73. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey 78. D, Gupta SK et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8.
74. Schiff E, Poordad I, Jacobson I, Flamm S, Bacon B, Lawitz E et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on inter- 79. feron responsiveness. J Hepatol 2008;48 (Suppl 2):S46.
75. Kwo P, Lawitz E, McCone J, Schiff E, VierlingJ, Pound D etal. Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC. J Hepatol 2008;48 (Suppl 2):S372. 80.
76. Klumpp K, Leveque V, Le Pogam S, Ma H, Jiang WR, Kang H et al. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-depen-dent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 2006;281:3793-9. 81.
77. Roberts SK, Cooksley G, Dore GJ, Robson R, Shaw D, Berns H etal. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008;48:398-406.
78. Reddy R, Rodriguez-Torres M, Gane E, Robson R, Lalezari J, Everson GT et al. Antiviral activity, phar-macokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007;46 (Suppl 1):862-3A.
79. Nelson D, Pockros P, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW et al. High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40 KD) and ribavirin followed by further 44 weeks of peginterferon alfa-2a and ribavirin. J Hepatol 2008;48 (Suppl 2):S371.
80. Le Pogam S, Seshaadri A, Kosaka A, Hu S, Kang H, Symons J et al. A high barrier to resistance may contribute to the robust antiviral effect demonstrated by R1626 in HCV genotype 1-infected treatment-naive patients. Hepatology 2007;46 (Suppl 1):813A.
81. Lalezari J, Gane E, Rodriguez-Torres M, Dejesus E, Nelson D, Everson GT et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with peg-IFN and ribavirin: interim results of R7128 500 mg BID for 28 days. J Hepatol 2008;48 (Suppl 2):S29.